Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-08-24 00:00:00 ET · period of report 2021-08-20 · accession 0001237899-21-000017 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-08-24 | 2021-08-23 | REGN | Fenimore Christopher R. | SVP Ctrl | S - Sale+OE | $655.31 | -4,781 | 27.8K | -15% | -$3.13M |
| D | 2021-08-24 | 2021-08-20 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $179.13 | +13.5K | 32.5K | +71% | +$2.42M |
| D | 2021-08-24 | 2021-08-20 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $0.00 | -13.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-23 | S | D | 4,576 | $655.00 | 27,944 | D | — | — | |
| 2 | Common | Common Stock | 2021-08-23 | S | D | 9 | $659.33 | 27,935 | D | — | — | (F2) Represents volume-weighted average price of sales of 9 shares of Company stock on August 23, 2021 at prices ranging from $659.28 to $659.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. |
| 3 | Common | Common Stock | 2021-08-23 | S | D | 23 | $660.33 | 27,912 | D | — | — | (F3) Represents volume-weighted average price of sales of 23 shares of Company stock on August 23, 2021 at prices ranging from $660.09 to $660.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. |
| 4 | Common | Common Stock | 2021-08-20 | M | A | 13,500 | $179.13 | 32,520 | D | — | — | |
| 5 | Common | Common Stock | 2021-08-23 | S | D | 88 | $661.89 | 27,824 | D | — | — | (F4) Represents volume-weighted average price of sales of 88 shares of Company stock on August 23, 2021 at prices ranging from $661.47 to $661.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. |
| 6 | Common | Common Stock | 2021-08-23 | S | D | 14 | $665.21 | 27,739 | D | — | — | |
| 7 | Common | Common Stock | 2021-08-23 | S | D | 1 | $662.78 | 27,823 | D | — | — | |
| 8 | Common | Common Stock | 2021-08-23 | S | D | 70 | $663.05 | 27,753 | D | — | — | (F5) Represents volume-weighted average price of sales of 70 shares of Company stock on August 23, 2021 at prices ranging from $663.00 to $663.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. |
| 9 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-08-20 | M | D | 13,500 | $0.00 | 0 | D | $179.13 · — to 2022-12-14 | 13,500 Common Stock | (F7) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |